Dr. Naj Sharif is a graduate of Southampton University, England (UK) where he received his BSc (Joint Honors: Biochemistry and Physiology) and his PhD (Neuroscience). Dr. Sharif has been in the pharmaceutical industry for >30-years holding leadership positions of increasing scope and responsibility, spanning Discovery Research, Drug Development and Regulatory Affairs. He has worked at Parke-Davis/Warner-Lambert (Pfizer), Syntex Research (Roche), Alcon-Novartis, and is currently at Santen Inc (Executive Director, R&D Division). Dr. Sharif’s 22-tenure at Alcon resulted in his contributions to the discovery/development and US FDA approvals of Travatan®, Patanol®, Simbrinza®, Izba® and Pazeo® to treat glaucoma/ocular hypertension and ocular allergies.
His research interest includes ocular function/disease, Prostanoid release, Ocular hypertension, Glaucoma, Ocular allergies, Neuroprotection, Receptor pharmacology, Drug discovery and development.